18F flutemetamol amyloid-beta PET imaging compared with 11CPIB across the spectrum of Alzheimer's disease

Not Applicable

• Conditions: Alzheimer' s disease

• Registration Number: JPRN-UMIN000019573
• Lead Sponsor: Shonan-Atsugi hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-02
• Study Completion: 2016-11-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

AD subjects were older than 56 years, and met the core clinical criteria of the NIA-Alzheimer's Association for probable AD. MCI subjects were older than 56 years, and met the Core Clinical Criteria for MCI proposed by the NIA-Alzheimer's Association. The normal cognitive status of HC subjects was required to be a MMSE score of 28 or greater and a CDR score of 0. All subjects or their caregiver provided written informed consent for participation. Participants were excluded if they had other systemic or brain diseases,including degenerative,vascular, depressive, traumatic, medical comorbidities, mixed disease, or traumatic brain injury.

Study & Design

• Study Type: Interventional
• Study Design: Not specified